Login Register Cart 0
Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Innovative Nanomaterials for Targeting Hypoxia to Improve Treatment for Triple-negative Breast Cancer

Author(s): Suman Kumar Ray and Sukhes Mukherjee*

Volume 18, Issue 4, 2024

Published on: 10 November, 2023

Page: [269 - 272] Pages: 4

DOI: 10.2174/0118722083270521231027074157

Price: $65

Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast cancer with a high rate of metastases, a short overall survival time, and a poor response to targeted therapy. Improving tumor hypoxia by lowering the oxygen consumption rate of breast tumor cells is a powerful strategy. A viable way to address this issue is to improve therapeutic efficacy by improving the effectiveness of radiation and overcoming drug resistance in TNBC treatment by controlling hypoxia in the tumor microenvironment. The failure of radiation and chemotherapy in TNBC is frequently caused by hypoxia. In TNBC therapy, novel nanomaterials are used for oxygen delivery or generation to affect the tumor microenvironment to improve the effects of ionizing radiation using nanoplatforms. One of the growing fields is novel nano-based drug delivery devices for hypoxic regions and hypoxia- inducible factor-1 (HIF1) targeted therapeutics. Biocompatible nanoparticles may be used in the treatment of TNBC patients in the clinic. Because of the rising market and competition, intellectual property rights (IPR), patents, and tactics may be critically considered. To better comprehend the current state of IPR and patents in cancer nanotechnology, this overview examines recent advances and sophisticated protection measures in this area.

Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019; 321(3): 288-300.
[http://dx.doi.org/10.1001/jama.2018.19323] [PMID: 30667505]
[3]
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016; 13(11): 674-90.
[http://dx.doi.org/10.1038/nrclinonc.2016.66] [PMID: 27184417]
[4]
Medina MA, Oza G, Sharma A, et al. Triple-negative breast cancer: A review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health 2020; 17(6): 2078.
[http://dx.doi.org/10.3390/ijerph17062078] [PMID: 32245065]
[5]
Ray SK, Mukherjee S. Epigenetic reprogramming and landscape of transcriptomic interactions: Impending therapeutic interference of triple-negative breast cancer in molecular medicine. Curr Mol Med 2022; 22(10): 835-50.
[http://dx.doi.org/10.2174/1566524021666211206092437] [PMID: 34872474]
[6]
Mukherjee S, Ray SK. Targeting tumor hypoxia and hypoxia-inducible factors (HIFs) for the treatment of cancer- A story of transcription factors with novel approach in molecular medicine. Curr Mol Med 2022; 22(4): 285-6.
[http://dx.doi.org/10.2174/156652402204220325161921] [PMID: 35603885]
[7]
Rey S, Schito L, Koritzinsky M, Wouters BG. Molecular targeting of hypoxia in radiotherapy. Adv Drug Deliv Rev 2017; 109: 45-62.
[http://dx.doi.org/10.1016/j.addr.2016.10.002] [PMID: 27771366]
[8]
Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11(6): 393-410.
[http://dx.doi.org/10.1038/nrc3064] [PMID: 21606941]
[9]
Li J, Shang W, Li Y, Fu S, Tian J, Lu L. Advanced nanomaterials targeting hypoxia to enhance radiotherapy. Int J Nanomedicine 2018; 13: 5925-36.
[http://dx.doi.org/10.2147/IJN.S173914] [PMID: 30319257]
[10]
Song X, Feng L, Liang C, Yang K, Liu Z. Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies. Nano Lett 2016; 16(10): 6145-53.
[http://dx.doi.org/10.1021/acs.nanolett.6b02365] [PMID: 27622835]
[11]
Wang P, Li X, Yao C, et al. Orthogonal near-infrared upconversion co-regulated site-specific O2 delivery and photodynamic therapy for hypoxia tumor by using red blood cell microcarriers. Biomaterials 2017; 125: 90-100.
[http://dx.doi.org/10.1016/j.biomaterials.2017.02.017] [PMID: 28235648]
[12]
Abbasi AZ, Gordijo CR, Amini MA, et al. Hybrid manganese dioxide nanoparticles potentiate radiation therapy by modulating tumor hypoxia. Cancer Res 2016; 76(22): 6643-56.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-3475] [PMID: 27758881]
[13]
Dorsey JF, Sun L, Joh DY, et al. Gold nanoparticles in radiation research: Potential applications for imaging and radiosensitization. Transl Cancer Res 2013; 2(4): 280-91.
[PMID: 25429358]
[14]
Liu H, Xie Y, Zhang Y, et al. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. Biomaterials 2017; 121: 130-43.
[http://dx.doi.org/10.1016/j.biomaterials.2017.01.001] [PMID: 28088075]
[15]
Schito L, Semenza GL. Hypoxia-inducible factors: Master regulators of cancer progression. Trends Cancer 2016; 2(12): 758-70.
[http://dx.doi.org/10.1016/j.trecan.2016.10.016] [PMID: 28741521]
[16]
Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors. Cancer Cell 2004; 5(5): 429-41.
[http://dx.doi.org/10.1016/S1535-6108(04)00115-1] [PMID: 15144951]
[17]
Cao L, Zhu Y, Wang W, Wang G, Zhang S, Cheng H. Emerging nano-based strategies against drug resistance in tumor chemotherapy. Front Bioeng Biotechnol 2021; 9: 798882.
[http://dx.doi.org/10.3389/fbioe.2021.798882] [PMID: 34950650]
[18]
Zhang Y, Sulfab M, Fernandez D. Intellectual property protection strategies for nanotechnology. Nanotechnol Rev 2013; 2(6): 725-42.
[http://dx.doi.org/10.1515/ntrev-2012-0089]
[19]
Viksnins AS, McCrackin AM. A guide to international patent protection: Intellectual property management in health and agricultural innovation: A handbook of best practices. 2007; vol 1 and 2: pp. 927-39.
[20]
Desai NP, Soon-Shiong P. Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane. US2010/0048499A1 2010.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy